What nuclear brain scan is used to assess Parkinsonian syndrome in adults with unexplained bradykinesia, rigidity, or tremor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nuclear Brain Imaging for Parkinsonian Syndromes

I-123 ioflupane SPECT/CT (DaTscan) is the nuclear brain scan used to assess Parkinsonian syndromes in adults with unexplained bradykinesia, rigidity, or tremor. 1

Primary Nuclear Medicine Study

I-123 ioflupane SPECT/CT is the gold standard nuclear medicine imaging modality for evaluating suspected Parkinsonian syndromes. 2, 3, 4 This scan binds to presynaptic dopamine transporters (DAT) on dopaminergic neurons in the striatum, demonstrating the loss of these neurons that characterizes Parkinson's disease and related disorders. 1

Key Diagnostic Features

  • The scan shows decreased radiotracer uptake in the striatum, typically progressing in a posterior-to-anterior pattern from the putamen to the caudate nuclei. 1

  • A normal I-123 ioflupane SPECT/CT essentially excludes Parkinsonian syndromes, making it highly valuable for ruling out these conditions. 1, 2

  • The test demonstrates abnormality early in the disease course, even before structural imaging like CT or MRI shows changes. 1, 4

Clinical Utility and Indications

Order I-123 ioflupane SPECT/CT when the clinical diagnosis remains uncertain after initial evaluation, specifically to differentiate true Parkinsonian syndromes from clinical mimics. 2, 3, 5

Specific Clinical Scenarios Where DaTscan Is Most Useful

  • Differentiating Parkinsonian syndromes (PD, MSA, PSP, CBD) from essential tremor - the scan will be abnormal in Parkinsonian syndromes but normal in essential tremor. 1, 6

  • Distinguishing drug-induced parkinsonism from neurodegenerative parkinsonism - drug-induced cases typically show normal scans. 1, 7

  • Evaluating patients with early, subtle symptoms where clinical diagnosis is challenging. 5

  • Assessing patients with suboptimal response to levodopa to determine if true nigrostriatal degeneration is present. 5

  • Clarifying diagnosis in patients with prominent action tremor that could represent either essential tremor or Parkinsonian tremor. 5

Important Limitations

  • DaTscan cannot differentiate between different types of Parkinsonian syndromes (PD vs. MSA vs. PSP vs. CBD) - all show abnormal dopaminergic depletion patterns. 1, 3

  • The scan is not indicated for monitoring disease progression in patients with established Parkinson's disease. 3

  • False negative scans can occur, highlighting the need for clinical follow-up even with normal results. 7

Alternative Nuclear Medicine Options

FDG-PET/CT

FDG-PET/CT has limited utility for initial Parkinsonian syndrome evaluation but can help differentiate specific atypical syndromes. 2, 4

  • FDG-PET is useful for discriminating Progressive Supranuclear Palsy (PSP) from idiopathic Parkinson's disease by demonstrating characteristic hypometabolism in the medial frontal and anterior cingulate cortices, striatum, and midbrain. 1

  • This modality is not first-line and should be reserved for cases where distinguishing between specific Parkinsonian syndromes is clinically necessary. 2

Fluorodopa F 18 PET

Fluorodopa F 18 Injection is FDA-approved for PET imaging to visualize dopaminergic nerve terminals in the striatum for evaluating adult patients with suspected Parkinsonian syndromes. 8

  • This is an alternative to I-123 ioflupane SPECT/CT but is less widely available in most U.S. centers. 3

Proper Diagnostic Algorithm

Always obtain MRI brain without contrast as the first imaging study before ordering any nuclear medicine scan. 2, 3, 4

Step-by-Step Approach

  1. First: Perform clinical assessment looking for cardinal features of bradykinesia plus either resting tremor, rigidity, or both. 2

  2. Second: Order MRI brain without IV contrast to rule out structural causes (vascular disease, normal pressure hydrocephalus, space-occupying lesions, focal abnormalities). 2, 3, 4

  3. Third: If clinical diagnosis remains uncertain after MRI, proceed with I-123 ioflupane SPECT/CT to assess nigrostriatal integrity. 2, 3

  4. Fourth: Ensure interpretation by a neurologist or movement disorder specialist who can integrate imaging findings with clinical context. 2

Critical Pitfalls to Avoid

  • Never skip structural MRI before ordering functional nuclear imaging - you may miss vascular parkinsonism, hydrocephalus, or structural lesions that mimic Parkinson's disease. 2, 3

  • Do not order DaTscan for patients with established Parkinson's disease experiencing worsening symptoms - it does not help monitor progression or guide treatment adjustments. 3

  • Avoid ordering amyloid PET/CT or tau PET/CT - there is no evidence supporting their use in evaluating Parkinsonian syndromes. 2

  • Do not rely solely on imaging results - clinical assessment by a movement disorder specialist remains the most important diagnostic element. 7, 9

Test Performance Characteristics

In clinically uncertain cases, DaTscan demonstrates high diagnostic accuracy. 5, 10

  • Positive percent agreement (abnormal scan with Parkinsonian syndrome diagnosis) ranges from 78-97% depending on the clinical scenario. 10

  • Negative percent agreement (normal scan with non-Parkinsonian diagnosis) ranges from 74-97%. 10

  • In a prospective series of 201 consecutive patients with clinically questionable nigrostriatal dopaminergic degeneration, DaTscan changed clinical diagnosis in 39.8% of patients and led to medication therapy changes in 70.1%. 5

References

Guideline

acr appropriateness criteria® movement disorders and neurodegenerative diseases.

Journal of the American College of Radiology, 2020

Guideline

Diagnosis and Treatment of Parkinson's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnostic Imaging for Parkinsonian Syndromes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnostic Modalities for Parkinson's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Practical Overview of 123I-Ioflupane Imaging in Parkinsonian Syndromes.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2024

Research

[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes.

Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.